Balloon Dilation of the Eustachian Tube
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This draft policy governs medical necessity, prior authorization, coverage, and coding for balloon dilation of the eustachian tube (BDET) for Medicare Advantage and Commercial members, including adult and pediatric criteria.
Pediatric indication (ages 8-17) stated as medically necessary when specific criteria are met following FDA expansion and supporting evidence.
Detailed explicit medical necessity criteria for adults including duration of symptoms (>=3 months), required diagnostic testing, failure of medical management, exclusion of other causes, reversibility testing, and contraindications.
CPT codes 69705 and 69706 designated medically necessary for Medicare Advantage Plans and Commercial Products when medical criteria are met.
Statement that evidence is sufficient to determine the technology results in an improvement in the net health outcome.
Medical Necessity and Coverage Criteria
Adult medical necessity
Covered when ALL of the following are met
Pediatric medical necessity
Covered in pediatric patients when ALL of the following are met
Initial Therapy
Covered when ALL of the following are met
Evidence from randomized controlled trials and observational studies demonstrates improvement in symptoms, tympanometry, and ability to Valsalva with durable effects through 52 weeks; pediatric evidence supportive though largely observational.
The following conditions and clinical scenarios are excluded and are considered contraindications to balloon dilation of the eustachian tube (BDET): patulous eustachian tube dysfunction; extrinsic reversible or irreversible causes such as craniofacial syndromes or other anatomic anomalies; history of radiation therapy to the nasopharynx; enlarged adenoid pads or a nasopharyngeal mass requiring alternate management; neuromuscular disorders causing ineffective ET opening; active systemic mucosal or autoimmune inflammatory disease affecting the nasopharynx/eustachian tube that is not in remission; chronic and severe atelectatic ears; and other pediatric-specific contraindications (for example, age <8 years, Trisomy 21, coagulopathy, dehiscent carotid on imaging without safeguards, active infection of the nasopharynx or middle ear, craniofacial anomalies) when present.
This policy is provided for informational purposes and is not a guarantee of payment. Coverage, benefits, and member financial responsibility are determined by the member's subscriber agreement, member certificate, or employer agreement, which supersede this medical policy. Providers should verify member eligibility and benefits with the plan prior to treatment.
Individuals who present with aural fullness but have a normal clinical examination and a normal tympanogram are specifically listed as not appropriate candidates for BDET and are considered not medically necessary for this procedure.
Services that are determined to be not medically necessary under this policy are not considered covered benefits under the member's plan unless the member was informed in advance and provided written agreement to assume financial responsibility. Providers should follow contractual participation agreements and plan processes regarding non-covered services and member billing.
Procedure Codes and Key Coding Details
Prior Authorization, Documentation, and Billing Actions
Prior Authorization Required
Prior authorization is required for Medicare Advantage plans and is recommended for Commercial products. Lack of prior authorization for Medicare Advantage services may result in denial of payment. Refer to the payer's Prior Authorization of Services, Treatments or Procedures policy for submission details and affected codes.
Required Diagnostic Documentation
Providers must document a comprehensive diagnostic assessment to support medical necessity before performing BDET. Documentation should include patient-reported questionnaires, detailed history and physical examination, tympanometry if the tympanic membrane is intact, nasal endoscopy (or nasopharyngoscopy in pediatrics), and comprehensive audiometry. Objective findings such as abnormal tympanogram (Type B or C) or abnormal tympanic membrane (retraction, effusion, perforation, or other abnormalities) should be included.
- Include copies or summaries of questionnaires and test results (tympanometry, audiometry, endoscopy)
- Document otoscopy findings and any prior tympanostomy tube response if applicable
Required Conservative Therapy Trial
Prior to BDET, providers must document a trial of conservative medical therapy and failure to respond. This includes management of contributing conditions (eg, allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux, temporomandibular joint disorder) and, when clinically indicated, a 4–6 week trial of intranasal corticosteroid therapy.
- Document duration and agents used for medical management of co-occurring conditions
- Document intranasal steroid therapy trial (4–6 weeks) when indicated
Requirement for Prior Medical Management
Procedure is indicated only when obstructive ETD persists despite appropriate prior medical management of reversible or contributing conditions. Ensure records show that alternative or reversible causes (eg, extrinsic obstruction, TMJ disorder, superior semicircular canal dehiscence, endolymphatic hydrops) have been evaluated and addressed as appropriate.
- Document evaluation and management of alternative causes and that symptoms persisted despite treatment
- If prior tympanostomy tubes were placed, document improvement while tubes were patent (if applicable)
Eligibility, Benefits Verification, and Member Financial Liability
Verify member eligibility, benefits, and any financial liability before scheduling the procedure. Services determined not medically necessary or non-covered under the member's benefit plan may not be billed to the member unless the member was informed in advance and provided written agreement to accept financial responsibility.
- Contact the provider call center or check the member's subscriber agreement for coverage details
- Obtain written informed financial agreement if proceeding with non-covered or not-medically-necessary services
Clinical Background and Evidence Summary
Eustachian tube dysfunction (ETD) occurs when the eustachian tube valve fails to open and/or close properly, resulting in impaired middle ear ventilation. Patients commonly report symptoms such as aural fullness, pressure, hearing loss, and otalgia, which may be persistent and affect quality of life. Left untreated, ETD can contribute to middle ear disease (for example, effusion, tympanic membrane retraction, chronic otitis media) and related complications. Balloon dilation of the eustachian tube (BDET) is a transnasal endoscopic procedure that dilates the cartilaginous portion of the tube using a balloon catheter, typically performed under general anesthesia and sometimes in conjunction with other otologic procedures, with the goal of improving tubal patency and middle ear ventilation.
Key Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.